

Natalia Kunst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3549163/publications.pdf>

Version: 2024-02-01

19
papers

286
citations

1307594

7
h-index

940533

16
g-index

21
all docs

21
docs citations

21
times ranked

334
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2023, 98, 122-130.	4.1	7
2	Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. <i>Medical Decision Making</i> , 2022, 42, 143-155.	2.4	6
3	Population-Based Newborn Screening for Germline <i>TP53</i> Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. <i>Journal of the National Cancer Institute</i> , 2022, 114, 722-731.	6.3	4
4	Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. <i>Value in Health</i> , 2022, , .	0.3	5
5	Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. <i>Medical Decision Making</i> , 2022, 42, 956-968.	2.4	4
6	Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. <i>Medical Care</i> , 2021, 59, 437-443.	2.4	2
7	Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1515-1522.	6.3	4
8	A Review of Web-Based Tools for Value-of-Information Analysis. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 645-651.	2.1	4
9	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	2.5	0
10	Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. <i>JAMA Internal Medicine</i> , 2021, 181, 1665-1668.	5.1	3
11	Breast Cancer Screening and Health Care Costs—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1553.	5.1	0
12	Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. <i>Pharmacoeconomics</i> , 2020, 38, 1135-1145.	3.3	109
13	Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2710-2718.	2.5	14
14	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. <i>Value in Health</i> , 2020, 23, 734-742.	0.3	51
15	Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. <i>JAMA Internal Medicine</i> , 2020, 180, 799.	5.1	14
16	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. <i>Medical Decision Making</i> , 2020, 40, 314-326.	2.4	28
17	Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With <i>ERBB2</i> (<i>HER2</i>)-Positive Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2027074.	5.9	10
18	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019, 22, 1102-1110.	0.3	12

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of diagnostic algorithms for peanut allergy in children. Journal of Allergy and Clinical Immunology, 2019, 143, 1243-1246.	2.9	2